CDK4 and breast carcinoma: Adding cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to ET significantly improves outcomes for patients with metastatic HR+ breast cancer, prolonging progression-free survival (PFS; refs. 8, 9).